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Abstract
Background: Human breast cancer is a heterogeneous disease, histopathologically, molecularly and phenotypically. The
molecular basis of this heterogeneity is not well understood. We have used a mouse model of DCIS that consists of unique lines
of mammary intraepithelial neoplasia (MIN) outgrowths, the premalignant lesion in the mouse that progress to invasive
carcinoma, to understand the molecular changes that are characteristic to certain phenotypes. Each MIN-O line has
distinguishable morphologies, metastatic potentials and estrogen dependencies.
Methods: We utilized oligonucleotide expression arrays and high resolution array comparative genomic hybridization (aCGH)
to investigate whole genome expression patterns and whole genome aberrations in both the MIN-O and tumor from four
different MIN-O lines that each have different phenotypes. From the whole genome analysis at 35 kb resolution, we found that
chromosome 1, 2, 10, and 11 were frequently associated with whole chromosome gains in the MIN-Os. In particular, two MIN-
O lines had the majority of the chromosome gains. Although we did not find any whole chromosome loss, we identified 3
recurring chromosome losses (2F1-2, 3E4, 17E2) and two chromosome copy number gains on chromosome 11. These
interstitial deletions and duplications were verified with a custom made array designed to interrogate the specific regions at
approximately 550 bp resolution.
Results: We demonstrated that expression and genomic changes are present in the early premalignant lesions and that these
molecular profiles can be correlated to phenotype (metastasis and estrogen responsiveness). We also identified expression
changes associated with genomic instability. Progression to invasive carcinoma was associated with few additional changes in
gene expression and genomic organization. Therefore, in the MIN-O mice, early premalignant lesions have the major molecular
and genetic changes required and these changes have important phenotypic significance. In contrast, the changes that occur in
the transition to invasive carcinoma are subtle, with few consistent changes and no association with phenotype.
Conclusion: We propose that the early lesions carry the important genetic changes that reflect the major phenotypic
information, while additional genetic changes that accumulate in the invasive carcinoma are less associated with the overall
phenotype.
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The paradigm that cancer progression is a multi-step proc-
ess, associated with multiple molecular changes as it
progresses from preneoplasia to invasive carcinoma [1],
has been challenged by recent molecular data. Gene
expression profiling and comparative genomic hybridiza-
tion (CGH) studies of breast cancer demonstrate that
early stages in the human breast cancer such as ductal car-
cinoma in situ (DCIS), a precursor lesion for invasive car-
cinoma, has most, if not all, of the molecular attributes of
the corresponding invasive carcinoma despite the distinct
pathological characteristics [2-5]. This is contrary to the
multi-step paradigm that centers on cumulative molecular
aberrations with progression. These data suggest an alter-
native view that the early lesions are already equipped
with the molecular changes responsible for tumorigene-
sis, despite the disparate histological characteristics
between the early lesions and the invasive carcinoma.
Breast cancer can be viewed as a heterogeneous disease
histopathologically, as well as molecularly. Molecular
profiling studies of breast cancer have shown that tumors
can be classified into subtypes based on their expression
patterns [6-8]. Pathologically, breast lesions are classified
by different categories, such as estrogen receptor (ER) sta-
tus, Her2 status and the degree of differentiation (tumor
grade). Both ER and Her2 status are important prognostic
factors and portend how a lesion responds to different
therapeutic strategies. Both DCIS and invasive ductal car-
cinoma (IDC) are categorized into three tumor grades [9].
DCIS lesions are also classified into different subtypes by
their histological morphology [10]. It is believed that the
different classes of lesions have common characteristics
that reflect certain clinical outcomes. Gene expression
studies of different pathological stages of breast cancer
have shown that different tumor grades are associated
with distinct expression signatures, confirming the molec-
ular basis for the differences in pathological classification;
the same studies show that the profiles of the different
stage lesions also have extensive similarities, suggesting
that there may not be as many molecular changes associ-
ated with tumor progression as was previously thought
[4].
Over the last several years, the MIN-O (mammary intraep-
ithelial neoplasia outgrowth) mouse model has been
shown to parallel various aspects of human breast cancer
development [11,12]. MIN (mammary intraepithelial
neoplasia) is an early mammary lesion that satisfies the
operational definition of premalignancy [13]. The MIN-O
mouse was established by transplanting a MIN lesion
from a young polyomavirus middle-T (PyVmT) transgenic
female mammary fat pad to a host fat pad [14]. The trans-
planted MIN lesion will grow from the transplanted loca-
tion to fill the host fat pad. The growth from the
transplanted MIN lesion is called MIN-outgrowth (MIN-
O). Since the MIN-O mouse eventually develops invasive
carcinoma within the MIN-O, tumor in this context refers
to invasive carcinoma that emerges within the MIN-O tis-
sue. Different lines of MIN-O mice, which were estab-
lished by transplanting MIN lesions to separate hosts,
have characteristic histopathology, metastatic potential,
and tumor latency, suggesting that MIN lesions have dif-
ferent biological outcomes despite the same initiating
oncogene (PyVmT) [11]. In addition, in depth gene
expression studies in one MIN-O mouse line, demon-
strated that the MIN-O and tumor tissues show strikingly
similar expression profiles between each early premalig-
nant lesion and its corresponding tumor pair [12]. Thus,
this model recapitulates the foundation of human DCIS
and the heterogeneous nature of the disease.
In the current study, we assessed the correlation between
certain biological outcomes to molecular changes associ-
ated with four different lines of MIN-O mice. In addition
to the gene expression analysis, we report for the first time
the utilization of high resolution array comparative
genomic hybridization (aCGH) to investigate whole
genome aberrations in both the MIN-O and tumor tissue.
In addition to this whole genome analysis (35 kb resolu-
tion), interstitial deletions were verified with a custom
made array designed to interrogate the specific regions at
approximately 550 bp resolution. We demonstrate that
expression and genomic changes are present in the early
premalignant lesions and that these molecular profiles
can be correlated to phenotype (metastasis and estrogen
responsiveness). Progression to invasive carcinoma was
associated with few additional changes in gene expression
and genomic organization. Therefore, in the MIN-O mice,
early premalignant lesions have the major molecular and
genetic changes required and these changes have impor-
tant phenotypic significance. In contrast, the changes that
occur in the transition to invasive carcinoma are subtle,
with few consistent changes and no association with phe-
notype. Therefore, we propose that the early lesions carry
the important genetic changes that reflect the major phe-
notypic information, while the additional genetic changes
accumulated in the invasive carcinoma are less associated
with the overall phenotype.
Methods
Mice
Standard techniques for mammary gland clearing and
mammary tissue transplantation, and the establishment
of the MIN-O lines, have been described previously
[11,12]. Three-week-old FVB female mice were purchased
from Charles River Laboratories (Wilmington, MA). Ani-
mals were maintained in a vivarium at the University of
California Davis campus under IACUC approved proto-
cols.Page 2 of 19
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To test MIN-O ovarian hormone sensitivity, a 1 mm3 piece
of a MIN-O tissue from each line was transplanted in the
gland-cleared #4 fat pads of 3-week-old virgin FVB female
mice. At the time of transplantation, the experimental
group (ovx, n = 8) was ovariectomized, while the control
group (intact, n = 4) received mock surgery without ova-
riectomy. At 5 weeks after transplantation, the MIN-O
sizes were measured by visually inspecting the transplan-
tation site under a dissecting microscope. Animals were
palpated weekly until a tumor was detected. The experi-
ment was concluded at day 99 post-transplantation. For
the tumor ovarian hormone sensitivity experiment, 1
mm3 pieces of tumor tissue that developed from various
MIN-O lines were transplanted to intact and ovx hosts (at
least 2 animals/4 tumors each for a tumor). Both intact
and ovx animals were terminated at the same time and the
tumor bearing fat pads were weighed.
Immunohistochemistry of formalin fixed tissues using
anti-estrogen receptor was performed as previously
described [15]. MIN-O transplanted fat pads from the
ovariectomy experiment were used to determine the ER
localization in the MIN-Os from the intact and ovariect-
omized hosts.
Mouse Genome CGH Microarrays
The Agilent Mouse Whole Genome CGH Microarray Kit
44A (G4414A, Agilent Technologies, Santa Clara, CA)
consists of roughly 43,000 60-mer oligonucleotide probes
that cover both exonic and intronic sequences. These
arrays were used to analyze the MIN-Os and tumors from
each line. These high resolution arrays have an average
spatial resolution of 35 kB, after removal of Repeat
Masked (-RM) [16]. Agilent uses SurePrint® technology
[17] to print this entire content on a standard 1" × 3" glass
slide.
In order to better define the length and boundaries of
interstitial regions that were identified as deleted or
amplified with the CGH 44A Microarray, a custom array
was generated to specifically interrogate these regions at a
higher resolution. Four regions were selected for analysis
(see Table 1). Approximately 38 K probes were used to
cover these regions for an average spacing of 547 bp (-
RM). Chromosomes 7 and 8 did not show any interstitial
aberrations or whole chromosome aberrations, so 4990
probes on these two chromosomes were utilized for the
normalization. In total, each "zoom-in" array contained
44,000 unique probes.
DNA was extracted from frozen MIN-O/tumor pairs iso-
lated from the same fat pads of MIN-O lines 4w-4 (n = 5
pairs), 4w-11 (n = 3 pairs), 8w-B (n = 3 pairs) and 8w-D
(n = 3 pairs). DNA from FVB/NCrl female livers was used
as the reference sample. Samples were prepared using the
direct labeling method, according to the Oligonucleotide
Array-Based CGH for Genomic DNA Analysis Protocol
(Version 2.0, available at [18]), with minor modifications
of the protocol. A total of 2 ug of digested purified DNA
was labeled, using the BioPrime Array CGH Genomic
Labeling kit (Invitrogen, Carlsbad, CA), for both the
experimental and reference channel. During the labeling,
cyanine 3-dUTP and cyanine 5-dUTP (Perkin Elmer,
Wellesley, MA) were incorporated in either the experi-
mental or the reference sample. For each sample, two
arrays were utilized in a dye-swap pair format, in which
the experimental sample and reference sample are each
labeled separately with cyanine 3 and cyanine 5, respec-
tively, and combined for the first array, and then labeled
in the reverse and combined for the second array. After
labeling, the corresponding experimental and reference
samples were combined and unincorporated nucleotides
were removed on a Microcon YM-30 apparatus (Milli-
pore, Billerica, MA). The purified sample was then hybrid-
ized onto a single CGH array in a solution containing
Mouse Cot-1 DNA (Invitrogen, Carlsbad, CA), Agilent
Table 1: Regions selected for high resolution custom CGH microarrays
Chromosomal Interval Base Pairs RM Length Cytobands Total Probes Genes Probe Density (-RM)
Chr2:130057657-134054840 3,997,184 1,593,942 qF1-qF2 4,393 97 547
Chr3:82669962-85356557 2,686,596 900,443 qE3-qF1 3,263 24 547
Chr11:42126777-46489372 4,362,596 1,560,848 qA5-qB1.1 5,120 49 547
Chr11:101602336-121653288 20,050,953 6,694,702 qD-qE2 24,413 584 547
Chr17:71771954-72520788 748,835 344,281 qE2 740 7 547
Totals 31,846,164 11,094,216 37,929 671
Chr7:1-141,766,352 141,766,352 58,864,541 2,900 28,587
Chr8:1-127,874,053 127,874,053 48,159,999 2,090 38,141
Print Controls 1,370
Totals 44,289Page 3 of 19
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lent, 5188–5226). Hybridization took place in a rotisserie
oven set to 65°C with a rotation speed of 20 rpm. The
washing and scanning of the slides was performed in an
ozone-free area to prevent the degradation of the cyanine
5 dye. Each slide was washed according to the manufac-
turer's recommendations with no Stabilization and Dry-
ing Solution. The slides were scanned on an Agilent DNA
Microarray Scanner B.
TIFF image files generated from the scanner were analyzed
using Agilent's Feature Extraction Software 8.1. This soft-
ware allows a standardized method of extracting data
using a standard CGH normalization protocol based on
all array features (44k_CGH_0605). The QC report gener-
ated was checked to ensure proper hybridization and
placement of the grid by the software. Data generated by
the Feature Extraction tool were loaded into CGH Analyt-
ics 3.1 (Agilent Technologies) to allow visualization of the
data. Dye swap pairs were combined to facilitate the visu-
alization of chromosomal aberrations. A smoothing aver-
age of 50 MB was used for the full genome arrays. Regions
of aberration (deleted or amplified) were determined by
the methodology of Barrett et al.[19].
Gene expression
Total RNA extraction and biotin-labeled probe synthesis
for gene expression analysis has been described previously
[11,12]. Frozen tissues from MIN-O lines 4w-4 (n = 3
MIN-Os, n = 3 tumors), 4w-11 (n = 3 MIN-Os, n = 3
tumors), 8w-B (n = 4 MIN-Os, n = 4 tumors) and 8w-D (n
= 4 MIN-Os, n = 3 tumors) and intact mammary fat pads
from 16-day prelactating FVB females (n = 2) were used
for hybridization onto Murine Genome U74Av2 Gene-
Chips (Affymetrix, Santa Clara, CA). The scanned images
were processed using GCOS 1.4, and then the data was
analyzed with GC-RMA in the ArrayAssist software pack-
age (Stratagene). GCRMA derived expression values were
log-transformed and analyzed in Arrayassist (t-test, une-
qual variance). Expression comparisons of all MIN-Os to
prelactating mammary glands, and all tumors to MIN-Os
were carried out in Arrayassist using t-test with FDR cor-
rection. 938 probes were differentially expressed with p <
0.01 in the MIN-Os vs prelactating comparison. 55 probes
were differentially expressed with p < 0.01 in the tumors
vs MIN-Os comparison. For expression comparisons of
samples from individual lines, profiles were compared in
Arrayassist using t-test without FDR correction and gene
lists were generated with criteria of p < 0.01.
Gene lists were subjected to pathway and function analy-
sis in Ingenuity Pathways Analysis (Ingenuity Systems,
Redwood City, CA). Annotation and gene ontology of
each probe was assigned by NetAffyx (Affymetrix, Inc).
The results from the statistical analyses described above
were analyzed by ErmineJ software [20] to determine the
number of significant gene ontology (GO) categories
using gene score resampling (GSR) [21]. Unfiltered t-test
results were imported into Erminej and analyzed using a
100,00 fold iteration re-sampling approach to determine
which Biological Processes categories were significant
below a Benjamini-Hochberg FDR-corrected p-value of
0.01.
For correlating the genomic changes to the expression dif-
ferences, chromosome locations of probes and known
genes were determined by the UCSC Genome Browser
[22]. For the analysis of whole chromosome gain of chro-
mosome 2, expression values of chromosome 2 probes (n
= 871) from 8w-B and 4w-4 MIN-Os were compared to
those from 8w-D and 4w-11 MIN-Os (t-test, unequal var-
iance). For chromosome 1, 10 and 11 probes (n = 652,
481, and 957, respectively), expression values from 8w-B
MIN-Os were compared to those from 8w-D, 4w-4, and
4w-11 (t-test, unequal variance). For the analysis of 2F,
3E, 17E and 11B, the corresponding probes were identi-
fied in UCSC Genome Browser. For 2F, 3E and 17E
probes, the average expression values of the 8w-D MIN-Os
were compared to the average expression values of 8w-B,
4w-4 and 4w-11 MIN-Os. For 11B probes, expression val-
ues of the 5189 MIN-O sample were compared to those of
the 5207 MIN-O sample.
Results
MINs are heterogeneous
Each transplantable MIN-O mouse line was established
from an individual MIN lesion from a Tg(PyVmT) mam-
mary fat pad. Each line has characteristic phenotypes
(Table 2), as previously described [11]. Distinct histologi-
cal features have been maintained in each MIN-O line
over multiple transplant generations. Detailed histologi-
cal analysis of MIN-O and tumor tissues from each MIN-
O line has been published previously [11]. The metastatic
potential of each MIN-O line is also different: 8w-D and
4w-11 MIN-Os are considered metastatic lines, while 8w-
B and 4w-4 are non-metastatic lines.
Ovarian hormone sensitivity of MIN-Os
ER status and ovarian hormone dependence is an impor-
tant diagnostic factor for mammary lesions. In general,
early mammary lesions developed in Tg(PyVmT) mam-
mary fat pads are ER-positive, but the expression of ER is
lost as the lesions progress to invasive carcinoma [23].
Previously, we showed that the MIN-O from the 8w-B
mouse line was ER-positive and also that MIN-O growth
was ovarian hormone-dependent, while the tumors
derived from the 8w-B MIN-O express significantly less ER
[15]. Since each MIN-O line represents individual mam-
mary lesions from Tg(PyVmT) fat pads that have distinct
characteristics, we tested the ovarian hormone depend-Page 4 of 19
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pads of ovariectomized host females (Table 3). Ovarian
ablation decreased the average MIN-O size and delayed
palpable tumor development, but with various degrees of
statistical significance in each line. In particular, ovariec-
tomy significantly inhibited both the MIN-O growth and
tumor latency in the 8w-B and 8w-D mice, while only the
MIN-O growth was significantly affected in the 4w-4 mice.
In the 4w-11 mice, the ovariectomy reduced the averaged
MIN-O size and increased tumor latency, but the effects
were not statistically significant. On the other hand, when
tumors that developed in ovary-intact MIN-O mice were
transplanted to ovariectomized hosts, the ovariectomy
did not inhibit tumor growth significantly in any of the
lines (data not shown). This demonstrates that the growth
of the tumors that have developed from the MIN-Os is not
dependent on ovarian hormones while the growth of the
MIN-Os is sensitive to the levels of these hormones.
ER expression in the 4w-4, 4w-11, 8w-B and 8w-D MIN-
Os were determined by immunohistochemistry of the
MIN-O transplanted fat pads (Table 2). In the intact hosts,
patches of strong nuclear ER-positive cells were present in
the 8w-B MIN-Os, while in the 8w-D MIN-Os, nuclear ER-
positive cells were also present, but with less intensity. In
4w-4 and 4w-11 MIN-Os from the intact hosts, nuclear ER
staining was rarely found and, if any, weak ER staining
was seen in the cytoplasm. In all four lines, MIN-Os from
the ovariectomized hosts had no nuclear ER-positive cells,
and reduced cytoplasmic staining, if any, compared to
those from the intact hosts (data not shown).
CGH analysis
To study genomic aberrations associated with MIN-O and
tumor samples, we utilized Agilent mouse CGH arrays on
14 MIN-O/tumor pairs. Genomic DNA from at least 3 dif-
ferent MIN-Os and the corresponding tumors from the
same fat pad were isolated from 4 different MIN-O mouse
lines.
Nine out of 14 MIN-Os carried some type of whole chro-
mosome gain (Figure 1B). The most common chromo-
some aberration was whole chromosome gain of
chromosome 2 (50%), followed by chromosome 11
(28.6%), 1 (28.6%), and 10 (21.4%). The corresponding
tumor samples carried the same chromosome gain(s),
except for one pair. Some of the tumors had acquired
additional genomic changes, suggesting that these
changes occurred during the MIN-O to tumor transition
(Figure 1C). The most common gain associated with the
tumor transformation was the whole chromosome gain of
chromosome 15 (4 out of 14 tumors) (Figure 1D). Other
whole chromosome gains associated with the progression
to tumor were found for chromosome 5, 6, 11, and 13 (1
out of 14 tumors, each). 36% (5/14) of the MIN-Os had
no major genomic abnormalities.
In addition to the whole chromosome gains, the MIN-Os
also exhibited chromosomal losses and/or gains of small
chromosomal regions. The most common regions deleted
were 2F1-2 (21.4% MIN-Os and tumors), 3E4 (7.1%
MIN-Os, 21.4% tumors), and 17E2 (7.1% MIN-Os,
21.4% tumors). Other regions that were found to have
deletions in one MIN-O/tumor pair were 12A, 16C2, and
Table 3: Effect of ovariectomy on MIN-O growth and tumor latency
MIN-O line MIN-O size at 5-weeks posttransplantation Tumor latency (in weeks)
Ovx
Control %FPF (n) % FPF (n) relative to control p-value Control TE50 Ovx TE50 p-value
4w-4 55.00 ± 10.00 (4) 24.29 ± 9.76 (7) 0.44 0.0008 10.1 >10.1 0.113
4w-11 37.50 ± 17.08 (4) 15.00 ± 18.17 (6) 0.40 0.08 10.2 12.1 0.118
8w-B* 67.50 ± 12.58 (4) 22.86 ± 7.56 (7) 0.34 <0.0001 4.9 11.1 0.002
8w-D 60.00 ± 0.00 (4) 10.71 ± 4.50 (7) 0.18 <0.0001 8.15 12.1 0.017
* from Namba et al 2005
Table 2: Characteristics of MIN-O lines
MIN-O line Major histological characteristics of MIN-Os* Metastasis Index* ER status of MIN-Os
4w-4 Solid chords & nests 0 Negative or cytoplasmic
4w-11 Microacini & organized cysts 0.63 Mostly cytoplasmic
8w-B Dysplastic cysts. Better differentiated. Microacinar structures. 0 Nuclear (+++)
8w-D Prominent and distinct microacinar patterns. Organized cysts. Patches of eosinophilic microacini. 0.47 Nuclear (+)
* From Maglione et al 2004.Page 5 of 19
(page number not for citation purposes)
BMC Cancer 2006, 6:275 http://www.biomedcentral.com/1471-2407/6/275
Page 6 of 19
(page number not for citation purposes)
Mouse whole genome CGH microarray data from MIN-Os and tumorsFig re 1
Mouse whole genome CGH microarray data from MIN-Os and tumors. A) Summary of array CGH data by MIN-O 
lines. Agilent mouse whole genome CGH microarray was used for genomic DNA from different MIN-O and tumor pairs from 
4w-4, 4w-11, 8w-B and 8w-D MIN-O mice. The graphs were generated with a smoothing average of 50 MB. Each Pair of MIN-
O and corresponding tumor from the same animal is represented with the same color (n = 4 for 4w-4, n = 3 each for 4w-11, 
8w-B and 8w-D). 4w-4 and 8w-B samples have multiple whole chromosome gains. 4w-11 and 8w-D samples are relatively 
genetically stable. B-E) Frequency of whole chromosome gains found in MIN-Os and tumors by array CGH. B) Distribution of 
whole chromosome gains in all MIN-Os studied with array CGH (n = 14). The most frequent gain is found on chromosome 2, 
followed by chromosome 1 and 11. C) Distribution of chromosome gains in all tumor samples studied with array CGH (n = 
14). Tumors have the same whole chromosome gains found in MIN-Os with a few additional gains. D) Frequency of whole 
chromosome gain events associated with MIN-O to tumor transition. Whole chromosome gains in tumors that are not found 
in the corresponding MIN-O samples are presumed to be acquired during the transition from MIN-O to tumor. E) Frequency 
of chromosome gains in 8w-B and 4w-4 samples (n = 8 for MIN-Os and tumors each). The majority of whole chromosome 
gains were found in the 8w-B and 4w-4 MIN-O lines.
Chromosome gain in MIN-Os
Chromosome gain in tumors
Chromosome gain 
from MIN-O to tumors
Chromosome gain 
in 8w-B and 4w-4 lines
B
C
D
E
A
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found in a single tumor.
Small interstitial gains (duplication) of a chromosome
material were not as common as interstitial chromosome
deletions. The only recurring small gain was 11B1.2
(7.1% MIN-Os, 14.2% tumors). Another area of interest
was duplication of 11E1 found in one tumor sample. This
area has been reported to be amplified in Tg(PyVmT)
tumors [24].
Expression changes associated with tumorigenesis
To understand the expression changes associated with
mammary tumorigenesis, as well as the molecular basis of
the heterogeneity of mammary lesions, we studied gene
expression profiles of MIN-Os and tumor samples. Highly
proliferative wild-type mammary gland (prelactating) was
used as the control, as it has the same proliferative index
as the early preneoplastic tissue (in contrast to the non-
proliferative quiescent mammary fat pad). The tissues
were analyzed with the Affymetrix GeneChip MG-U74Av2
oligonucleotide arrays.
The gene expression profiles of the MIN-Os were dramat-
ically different from that of the proliferating mammary
glands. 937 probes (899 genes – comprised of 19
unknown probes, 103 unknown genes or ESTs, and 777
known genes) were differentially expressed (p < 0.01).
293 out of the 777 known genes were down-regulated in
MIN-Os and 484 out of the 777 genes were over-expressed
in MIN-Os. The majority of these genes were involved in
cell cycle and/or cell death functions [see Additional file
1].
In general, the expression profiles of tumors were very
similar to those of the MIN-Os. Only 55 probes (50
known genes) were differentially expressed (p < 0.01),
and they were all down-regulated (Table 4). Nine of these
genes are related to extracellular matrix (TNXB, SGCE,
DPT, LUM, GSN, LAMA2, C1R, CLEC3B, DF, LPL, NID,
RBP4, RETN); another set of noticeable genes are Igfbp-6
and PPP2R5a, which are anti-proliferative genes. Since
many of these genes are known to be found in stroma, we
examined the expression level of an epithelial marker,
Krt2-8 (Keratin 8), in the samples to determine whether
the expression changes are due to the change in the epi-
thelial component of the tissues. Krt2-8 expression
between the MIN-Os and tumors was not statistically sig-
nificantly different (p = 0.1855, t-test, FC = 1.2). In previ-
ous studies, TaqMan quantitative PCR was utilized to
confirm the expression of several genes (decorin, IGFBP2,
Thrsp, Sncg, SerpinG1) in MIN-O and tumor pairs and
showed that this data correlated with the direction and
fold change of the microarray data [12]. In addition,
immunohistochemistry studies demonstrated that the
gene expression differences are not due to differences in
the epithelial and stromal abundance in the MIN-O and
tumor but rather due to inherent differences in the tissues.
Thus, it is unlikely that the significant down-regulation of
these 50 genes in the tumors is solely due to the enrich-
ment of the stroma in the MIN-Os.
Molecular changes associated with each MIN-O line
Recurring genomic aberration by MIN-O lines
When CGH results were analyzed for each MIN-O line, we
found recurring genomic changes that were specific to cer-
tain lines. MIN-Os from 8w-B and 4w-4 mice carried large
chromosome aberrations, frequently including multiple
chromosome gains, while large chromosome aberrations
were rare in the 4w-11 and 8w-D lines (Figure 1A&E).
100% of 8w-B MIN-Os carried whole chromosome gain
of chromosomes 1, 2, 10 and 11. 80% of 4w-4 MIN-Os
carried whole chromosome gain of chromosome 2.
Tumors arising from both MIN-O lines (8w-B and 4w-4)
often acquired additional chromosome gain(s) (6 out of
8 tumors), although the majority of the cases were limited
to a gain of one chromosome, and there were no recurring
chromosome gains found in tumors, except for chromo-
some 15.
In the MIN-O lines with whole chromosome gains, the
gene expression pattern reflected the genomic changes.
When expression of genes on chromosome 2 from the
MIN-O lines with whole chromosome gains (8w-B and
4w-4) were compared to those from the lines with normal
chromosome number (4w-11 and 8w-D), 60 probes had
significantly higher expression (p < 0.01) in 8w-B and 4w-
4 MIN-Os, while only 5 probes had significantly lower
expression, when compared to 4w-11 and 8w-D MIN-Os
(Table 5). For chromosomes 1, 10 and 11, which were
gained in 8w-B MIN-Os, genes on these chromosomes
had higher expression in 8w-B MIN-Os compared to the
rest of the MIN-Os (Table 6).
In-depth analysis of the data found that all the 8w-D sam-
ples carried deletions of 2F1-2, 3E4, and 17E2 regions. A
pair of MIN-O and tumor samples from one 8w-D animal
(5189) had the same amplification of 11B1 region. We
also found a large amplification of 11E in a tumor from
one 4w-4 animal. Among the four MIN-O lines, we found
the least amount of chromosome abnormality in 4w-11
samples. 4w-11 samples did not carry any whole chromo-
some aberrations, or large duplications. In one MIN-O/
tumor pair of 4w-11, we found a small deletion in the 3D-
E1 region.
Zoom-in arrays
To confirm the small deletions and duplications detected
by the whole genome arrays, a custom CGH array for the
11B, 11E, 2F, 3E, and 17E regions was designed (see mate-Page 7 of 19
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able to more finely map the deleted regions in the 8w-D
samples as follows: 111kb on 2F1-2 (chr2: 130,621,986-
131,735,939), 383 kb on 3E4 (chr3: 83,909,586-
84,292,657), 59 kb on 17E2 (chr17: 72,077,340-
72,137,044) (Figure 2). The genes in these regions are:
Hspa12b, 1700037H04Rik, Spef1, Cenpb, cdc25b,
2310035K24Rik, D430028G21Rik, Pank2, Rnf24, Smox,
Adra1d, 1600014E20Rik, Prnp, Rassf2, Slc23a2, on chro-
mosome 2; Trim2, 6330505N24Rik, on chromosome 3;
and 2810410M20Rik on chromosome 17. 10 out of 16
genes in the deleted region on chromosome 2 are repre-
sented on the 74Av2 array by 10 probes (Table 7). In 6 out
of the 10 probes, the average expression in the 8w-D MIN-
Os was lower as compared to the MIN-Os from other lines
(Table 7). The deleted regions in 3E and 17E were covered
Table 4: Tumor vs MIN-O expression differences
Probe Set ID Gene Title Gene Symbol FC in tumors GO biological function
99104_at adiponectin, C1Q and collagen domain containing Adipoq -21.75 Lipid metabolism, Organic acid 
metabolism
99671_at adipsin Adn -35.98
98924_at ADP-ribosyltransferase 3 Art3 -2.55
92537_g_at adrenergic receptor, beta 3 Adrb3 -2.88
102327_at amine oxidase, copper containing 3 Aoc3 -3.66 Cell adhesion
96785_at ankyrin repeat domain 47 Ankrd47 -2.04
104761_at anthrax toxin receptor 2 Antxr2 -1.60
160375_at carbonic anhydrase 3 Car3 -20.83
101539_f_at carboxylesterase 3 Ces3 -4.06 Lipid metabolism, Organic acid 
metabolism
102016_at cell death-inducing DFFA-like effector c Cidec -4.79
95415_f_at complement component 1, r subcomponent C1r -2.64
92224_at C-type lectin domain family 3, member b Clec3b -5.87
96346_at cysteine dioxygenase 1, cytosolic Cdo1 -9.76 Organic acid metabolism
93996_at cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 -3.54
96742_at dermatopontin Dpt -5.06 Cell adhesion
103031_g_at dynamin 1 Dnm1 -2.21
92535_at early B-cell factor 1 Ebf1 -1.81
100567_at fatty acid binding protein 4, adipocyte Fabp4 -2.31
92441_at fibroblast activation protein Fap -2.27
101991_at flavin containing monooxygenase 1 Fmo1 -3.20
93040_at FXYD domain-containing ion transport regulator 1 Fxyd1 -2.69
93750_at gelsolin Gsn -5.43
102373_at glutamyl aminopeptidase Enpep -2.86
99108_s_at growth hormone receptor Ghr -1.99
92833_at histidine ammonia lyase Hal -2.25 Organic acid metabolism
95546_g_at insulin-like growth factor 1 Igf1 -2.07
103904_at insulin-like growth factor binding protein 6 Igfbp6 -4.34
92366_at laminin, alpha 2 Lama2 -3.25 Cell adhesion
103083_at lipase, hormone sensitive Lipe -2.46 Lipid metabolism
160083_at/95611_at lipoprotein lipase Lpl -5.18 Lipid metabolism
93353_at lumican Lum -9.33
97520_s_at neuronatin Nnat -5.92
100120_at nidogen 1 Nid1 -2.19 Cell adhesion
160481_at phosphoenolpyruvate carboxykinase 1, cytosolic Pck1 -2.61 Lipid metabolism, Organic acid 
metabolism
102763_at plasma membrane associated protein, S3-12 MGI:1929709 -8.13
93826_at protein phosphatase 2, regulatory subunit B (B56), alpha isoform Ppp2r5a -1.43
102366_at resistin Retn -10.89
97835_at retinoic acid receptor responder (tazarotene induced) 2 Rarres2 -6.19
96047_at retinol binding protein 4, plasma Rbp4 -4.08
104445_at RIKEN cDNA 4631408O11 gene 4631408O11Rik -5.20
101861_at sarcoglycan, epsilon Sgce -1.62
102707_f_at serine (or cysteine) peptidase inhibitor, clade A, member 3C Serpina3c -1.94
97429_at SNF related kinase Snrk -1.65
92582_at solute carrier family 1 (neutral amino acid transporter), member 5 Slc1a5 -1.94
160320_at sorbin and SH3 domain containing 1 Sorbs1 -2.74 Cell adhesion
94056_at/94057_g_at stearoyl-Coenzyme A desaturase 1 Scd1 -2.76 Lipid metabolism, Organic acid 
metabolism
103087_at sulfotransferase family 1A, phenol-preferring, member 1 Sult1a1 -1.68 Lipid metabolism
103568_at sushi-repeat-containing protein Srpx -2.84
104280_at synuclein, gamma Sncg -4.63
102916_s_at/161907_s_at tenascin XB Tnxb -4.73 Cell adhesion
160547_s_at thioredoxin interacting protein Txnip -2.83
99052_at zinc finger homeobox 1a Zfhx1a -1.63Page 8 of 19
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98886_at for 2810410M20Rik). The expression of both
genes was lower in 8w-D MIN-Os compared to the other
MIN-Os.
The detailed breakpoints of the two duplicated regions
(11B and 11E) were confirmed by the zoom-in array. The
breakpoints on 11qB were 42,631,278-44,744,905, which
spanned the following genes: Pttg1, D11Ertd730e,
C1qtnf2, Fabp6, Ttc1, Adra1b, Il12b, Ublcp1,
3732413I11Rik, Ebf1 (Table 8). These genes are repre-
sented by 11 probes on the 74Av2 array, and the expres-
sion of these genes in the 5189 MIN-O (the 8w-D MIN-O
sample with the 11B amplification) are higher than in the
5207 MIN-O (an 8w-D MIN-O without the amplifica-
tion). The 11qE1 region seems to be comprised of regions
with varying degrees of amplification, starting from
102,146,284 to the end (121,647,795) (data not shown).
In general, the interstitial aberrations identified show con-
comitant gene expression changes and suggest that there
is a DNA dosage-gene expression relationship.
Gene expression associated with each MIN-O line
Since each MIN-O line has distinct biological characteris-
tics, we expected to find unique gene expression features
for each line. To identify unique expression changes asso-
ciated with each MIN-O lines, we subjected each list of
MIN-O vs. PL differences to GSR GO analysis. There were
only 5 significant GO biological function terms (p < 0.05)
in the 4w-4 line (DNA-dependent DNA replication, chro-
matin assembly or disassembly, nucleosome assembly,
regulation of cyclin dependent protein kinase activity,
organic acid biosynthesis), of which the first four func-
tions were significant in the other lines (Table 9). The 4w-
11 line was characterized by three highly significant I-kap-
paB/NF-kappaB pathway-related functions (p < 0.0001)
(Table 10). The cell cycle and mitotic spindle/microtubule
related functions were particularly highly represented in
8w-B line (Table 11). The 8w-D line had over-representa-
tion of specific signaling pathways (Wnt, Ras and MAPK),
as well as ECM-related functions (Table 12). Moreover,
certain functions were common in multiple MIN-O lines.
The immune response-related functions, as well as the I-
kappaB/NF-kappaB cascade related functions, were very
highly represented in the 4w-11 and 8w-D lines. The func-
tions related to UV light/radiation response were highly
significant in the 4w-11 and 8w-D lines. 8w-B and 8w-D
lines shared angiogenesis and steroid biosynthesis related
functions as highly significant biological functions
Although the comparison of all tumors vs. all MIN-Os
identified a small number of down-regulated genes, there
was no one gene common to the tumor vs. MIN-O gene
lists from the four MIN-O lines [see Additional file 2].
Because the expression profiles of tumors were very simi-
lar to the corresponding MIN-Os, GO analysis did not
result in any significant functional terms. However each
line had characteristic expression differences of genes that
suggest changes in tumor-associated functions. Tumors
developed from 4w-4 MIN-Os were characterized by
down-regulation of immunoglobulin and up-regulation
of actin and myosin (3- to 4-fold change). Tnfrsf11/
RANK, receptor activator of NfκB [25], and RalA, which is
a critical component for Ras-induced tumorigenesis [26]
were also up-regulated in these tumors. In 4w-11 tumors,
CEBPA, which is associated with breast cancer progression
[27] was down-regulated and CEBPB, a gene found to be
up-regulated in breast cancer as well as mouse mammary
tumors [28], is up-regulated. Moreover, the 4w-11 tumors
exhibited down-regulation of actin, myosin, Ig, and MHC
Table 5: Chromosome 2 gene expression in MIN-O lines with whole chromosome gains (8w-B & 4w-4 vs. 8w-D & 4w-11)
# of probes
p-value increased decreased total probes
Chr 2 <0.01 60 5 871
<0.05 143 15
Table 6: Chromosome 1, 10 and 11 gene expression differences in MIN-O lines with whole chromosome gains (8w-B vs. 8w-D, 4w-4 & 
4w-11)
# of probes
p-value increased decreased total probes
Chr 1 <0.01 78 11 652
<0.05 217 24
Chr 10 <0.01 61 4 481
<0.05 139 14
Chr 11 <0.01 121 11 957
<0.05 255 36Page 9 of 19
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decreased in highly metastatic breast cancer cell lines [29],
as well as decreased during progression to tumor [30]. 8w-
B tumors had up-regulation of PLK [31] and 8w-D tumors
had up-regulation of Epha2 [32].
Molecular changes associated with biological 
characteristics
Molecular changes in MIN-Os with genetic instability (lines 8w-B and 
4w-4)
dysregulation of mitotic spindle and chromosome segre-
gation related genes To further understand the basis of
chromosome instability in the MIN-Os, we assessed gene
expression profiles of the genetically unstable MIN-O
lines – 8w-B and 4w-4. Seven out of eight MIN-O samples
from these two lines had whole chromosome gain of
chromosome 2. The two lines had 13 genes from chromo-
some 2 in common in the gene expression comparison
between MIN-O and PL [see Additional file 3]. Among
these 13 genes, all but one was over-expressed in the MIN-
Os. Aurora kinase A (Aurka/STK6/STK15) was the most
dramatically over-expressed (9- to 10-fold).
Aurka regulates centrosome duplication and mitotic spin-
dle assembly. Other genes involved in spindle assembly
(Ran, Tuba1, Tubb6, Kif22, Nde1, Ndrg1) and centro-
some duplication and sister chromatid segregation (Plk1,
Gadd45a, Apc11, Cdc20 and Cdkn1a) were also dysregu-
lated. In addition, genes up-regulated in 8w-B and 4w-4
MIN-Os included a large group of E2F4 regulated genes
(H2AFZ, RFC2, RFC4, ZNF305, KIF22, RPA3, RRM1,
CDK4, CDC2, PLK1, PSMA4, and TK1) [33].
Expression profiles associated with metastatic MIN-Os
8w-D and 4w-11 are the two MIN-O lines with highest
metastatic index (Maglione 2004). From our GO analysis
Table 7: Expression in the deleted region (2F1-2, chr2: 130,621,986-131,735,939)
Genes U74Av2 probe ID lower expression in 8w-D MIN-Os*
Hspa12b
1700037H04Rik 97210_at x
Spef1/4931426K16Rik 93475_at x
Cenpb 99486_at x
cdc25b 99012_at
2310035K24Rik 96819_at
D430028G21Rik
Pank2
Rnf24 97200_f_at x
Smox
Adra1d
1600014E20Rik 161097_at
Prnp 100606_at x
Prnd
Rassf2 94771_at
Slc23a2 104267_at x
* determined by 8w-D MIN-Os compared to rest of the MIN-O samples
Table 8: Expression in the duplicated region (11B, ch11:42,631,278-44,744,905)
Genes U74Av2 probe ID higher expression in 5189MINO**
Pttg1 101026_at x
D11Ertd730e 160772_I_at x
161428_at x
C1qtnf2
Fabp6 99977_at x
Ttc1 96921_at x
161887_r_at x
Adra1b 92340_at x
Il12b 100779_at x
Ublcp1 94865_at x
3732413l11Rik 96104_at x
Ebf1 92535_at x
** determined by 5189 MIN-O compared to 5207 MIN-OPage 11 of 19
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lation of significant number of genes that are involved in
immune-related responses and apoptotic program. The
MIN-Os from these two lines share 209 probes that are
dysregulated [see Additional file 4]. Among the 209
probes (186 genes and 18 ESTs), 42 genes are unique to
these two lines. Examples of these unique genes include
Serpine2, which is overexpressed in metastatic cancer;
Ctnnb1, Fliih, Pdlim4/Ril, all of which affect migratory
behavior of cells; and Gas6, which is a ligand for the Axl
oncogene [34].
The metastasis signature genes in human cancer [35] have
been reported to be predictive of a high metastatic rate in
mouse tumors [36]. 14 out of these 17 signature genes are
represented in the MG-U74Av2 array. We compared the
expression of these 14 genes in both MIN-Os and tumors,
between the two most metastatic MIN-O lines (8w-D and
4w-11) and the two least metastatic MIN-O lines (8w-B
and 4w-4). We did not find significant correlation of the
expression trends between what has reported with human
metastatic breast cancer and our metastatic MIN-O lines
(data not shown), yet, further analysis and comparison to
the human data is required in order to identify potential
correlated GO terms and pathway hubs that may better
reflect similarity in the model and the human data.
Expression profiles associated with estrogen sensitivity
8w-B and 8w-D MIN-Os are more sensitive to ovarian
ablation than other lines. Transcript levels of ERs in the
8w-B and 8w-D MIN-Os tend to be slightly higher than
the 4w-4 and 4w-11 MIN-Os [see Additional file 5], which
is consistent with ER expression found in the immunohis-
tochemical analysis. Moreover, the expression of cyp19a1,
an aromatase which catalyzes essential reactions for estro-
gen biosynthesis, is also slightly but statistically signifi-
Table 9: Significant biological functions for MIN-O vs PL expression differences for 4w-4 line
Name GO ID Corrected P-value
Highly significant GO functions
DNA-dependent DNA replication GO:0006261 0.00E+00
organic acid biosynthesis GO:0016053 0.00E+00
chromatin assembly or disassembly GO:0006333 0.00E+00
nucleosome assembly GO:0006334 0.00E+00
regulation of cyclin dependent protein kinase activity GO:0000079 2.68E-02
Table 10: Significant biological functions for MIN-O vs PL expression differences for 4w-11 line
Name GO ID Corrected P-value
I-kappB/NF-kappaB
regulation of I-kappaB kinase/NF-kappaB cascade GO:0043122 0.00E+00
positive regulation of I-kappaB kinase/NF-kappaB cascade GO:0043123 0.00E+00
I-kappaB kinase/NF-kappaB cascade GO:0007249 0.00E+00
apoptotic program
apoptotic program GO:0008632 0.00E+00
Immune response
lymphocyte differentiation GO:0030098 7.04E-03
antigen presentation, exogenous antigen GO:0019884 1.59E-02
xenobiotic metabolism GO:0006805 2.02E-02
T-cell activation GO:0042110 2.72E-02
response to xenobiotic stimulus GO:0009410 2.68E-02
T-cell differentiation GO:0030217 2.71E-02
response to bacteria GO:0009617 2.87E-02
regulation of immune response GO:0050776 3.35E-02
defense response to bacteria GO:0042742 3.87E-02
antigen presentation GO:0019882 4.21E-02
Reponse to radiation/UV
response to radiation GO:0009314 6.37E-03
phototransduction GO:0007602 1.53E-02
detection of light GO:0009583 1.91E-02
response to light GO:0009416 2.79E-02Page 12 of 19
(page number not for citation purposes)
BMC Cancer 2006, 6:275 http://www.biomedcentral.com/1471-2407/6/275cantly higher in the 8w-B and 8w-D lines (fold change =
1.07, p = 0.0068). In these lines, steroid biosynthesis (p =
0.0345 for 8w-B, p = 3 × 10-6 for 8w-D) and sterol metab-
olism (p = 0.0416 for 8w-D) were represented as highly
significant GO functions (Table 7). In addition, angiogen-
esis related functions were also significant. 271 probes
(114 probes unique to only these two lines) were differen-
tially expressed in both 8w-B and 8w-D MIN-Os [see
Additional file 6]. Genes dysregulated only in 8w-B and
8w-D MIN-Os include proteins that interact with estrogen
or ER, such as Abcg1, Gnai2, Fbln1, Nr4a1, Jun (all up-
regulated), and Strn and Cyp1b1 (both down-regulated).
Also, NfκB pathway genes – Nfkb2, Relb, and Bcl10 –
were down-regulated.
Discussion
Major chromosome abnormalities associated with 
tumorigenesis are present at the MIN-O stage
This study is the first molecular analysis of mammary
tumor progression in the four MIN-O mouse lines, and it
shows that MIN-Os, mouse mammary premalignant
lesions, are already genetically and molecularly advanced,
with molecular and genomic profiles similar to those of
invasive tumors. This study also confirms that these
lesions, which originated in the same organ site, are genet-
ically heterogeneous, as reflected from their morphologi-
cal, genomic, and gene expression characteristics. We
hypothesize that even with the same initiating oncogene,
the resulting early premalignant lesions and subsequent
tumors will have different groups of biologically distinct
characteristics that are determined by the genetic changes
already present in the early lesions – in this case, in the
MIN-Os.
From the whole genome analysis of MIN-O and tumor
samples by the array CGH, we found that most lesions
already have chromosome aberrations at the MIN-O
stage. The results from the expression arrays mirror the
CGH results in that major expression changes were seen in
the MIN-O stage and expression changes between the
MIN-Os and tumors are surprisingly relatively few. The
finding that the MIN-Os already have the major genomic
and expression changes that have previously been associ-
ated with tumorigenesis is consistent with observations in
human breast cancer [3,4]. Human DCIS has been found
to have the same chromosome alterations found in inva-
Table 11: Significant biological functions for MIN-O vs PL expression differences for 8w-B line
Name GO ID Corrected P-value
Spindle/Microtubule
mitotic spindle organization and biogenesis GO:0007052 0.00E+00
spindle organization and biogenesis GO:0007051 0.00E+00
microtubule cytoskeleton organization and biogenesis GO:0000226 0.00E+00
microtubule-based movement GO:0007018 4.70E-07
chromosome segregation GO:0007059 4.32E-03
microtubule polymerization GO:0046785 1.59E-02
microtubule polymerization or depolymerization GO:0031109 1.97E-02
M phase specific microtubule process GO:0000072 3.32E-02
Cell cycle
regulation of mitosis GO:0007088 0.00E+00
cell cycle checkpoint GO:0000075 0.00E+00
interphase of mitotic cell cycle GO:0051329 0.00E+00
G1/S transition of mitotic cell cycle GO:0000082 0.00E+00
negative regulation of cell cycle GO:0045786 6.08E-03
G2/M transition of mitotic cell cycle GO:0000086 1.29E-02
mitotic checkpoint GO:0007093 1.28E-02
regulation of cyclin dependent protein kinase activity GO:0000079 1.25E-02
G1 phase of mitotic cell cycle GO:0000080 1.41E-02
traversing start control point of mitotic cell cycle GO:0007089 1.67E-02
cell cycle arrest GO:0007050 1.67E-02
mitotic anaphase GO:0000090 2.63E-02
anaphase GO:0051322 2.72E-02
prophase GO:0051324 2.81E-02
Angiogenesis
blood vessel morphogenesis GO:0048514 6.37E-03
angiogenesis GO:0001525 1.01E-02
blood vessel development GO:0001568 9.73E-03
Steroid
steroid biosynthesis GO:0006694 3.45E-02Page 13 of 19
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sion level, ADH, DCIS, and IDC from the same individual
are highly similar to each other [4,37].
Our findings show whole chromosome gains in the MIN-
Os and tumors to be fairly common, while no whole chro-
mosome loss was observed. This is consistent with LOH
analysis that did not find increased chromosome loss or
large deletions in Tg(PyVmT) mammary tumor [38]. A
previous CGH study by Hodgson et al. found that chro-
mosomes 2, 11 and 15 most often had recurrent gains in
PyVmT mammary tumors [24]. Indeed, the tumor sam-
ples we analyzed frequently had whole chromosome
gains of these chromosomes, as well as chromosomes 1
Table 12: Significant biological functions for MIN-O vs PL expression differences for 8w-D line
Name GO ID Corrected P-value
Response to radiation/UV
phototransduction GO:0007602 0.00E+00
detection of light GO:0009583 0.00E+00
response to radiation GO:0009314 0.00E+00
response to light GO:0009416 0.00E+00
response to UV GO:0009411 2.88E-02
Apoptosis
apoptotic program GO:0008632 0.00E+00
Immune response
complement activation, classical pathway GO:0006958 9.56E-03
positive regulation of immune response GO:0050778 1.15E-02
regulation of immune response GO:0050776 1.36E-02
T-cell activation GO:0042110 2.23E-02
antigen processing GO:0030333 2.25E-02
cellular defense response (sensu Vertebrata) GO:0016066 2.32E-02
antimicrobial humoral response GO:0019730 2.58E-02
positive regulation of lymphocyte activation GO:0051251 2.60E-02
xenobiotic metabolism GO:0006805 2.58E-02
symbiotic interaction between host and other organism GO:0044404 2.56E-02
oxygen and reactive oxygen species metabolism GO:0006800 3.21E-02
complement activation GO:0006956 3.21E-02
response to xenobiotic stimulus GO:0009410 3.97E-02
lymphocyte differentiation GO:0030098 3.94E-02
pathogenesis GO:0009405 3.96E-02
T-helper 1 type immune response GO:0042088 4.19E-02
detection of biotic stimulus GO:0009595 4.49E-02
cytokine and chemokine mediated signaling pathway GO:0019221 4.72E-02
antigen presentation, endogenous antigen GO:0019883 4.71E-02
lymphocyte proliferation GO:0046651 4.90E-02
antigen presentation GO:0019882 8.19E-03
Angiogenesis
blood vessel morphogenesis GO:0048514 8.92E-03
blood vessel development GO:0001568 1.17E-02
angiogenesis GO:0001525 1.47E-02
ECM
extracellular structure organization and biogenesis GO:0043062 3.18E-02
extracellular matrix organization and biogenesis GO:0030198 3.15E-02
cell-matrix adhesion GO:0007160 4.31E-02
Signaling pathways
I-kappaB kinase/NF-kappaB cascade GO:0007249 0.00E+00
regulation of I-kappaB kinase/NF-kappaB cascade GO:0043122 2.38E-02
positive regulation of I-kappaB kinase/NF-kappaB cascade GO:0043123 2.35E-02
Wnt receptor signaling pathway GO:0016055 1.16E-04
Ras protein signal transduction GO:0007265 4.61E-03
inactivation of MAPK GO:0000188 2.43E-02
Steroid
steroid biosynthesis GO:0006694 3.27E-06
sterol metabolism GO:0016125 4.16E-02Page 14 of 19
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consistently during the transition from MIN-O to tumor
in the different lines. Moreover, as expected from the CGH
analysis, there seem to be no common expression changes
that are associated with every MIN-O to tumor transition
event.
The whole genome analysis with aCGH also led to the
identification of areas of small deletions. Moreover, using
a custom-designed array, the aberrations were confirmed
and the breakpoints were refined. The smallest area con-
firmed by the zoom-in array was the 59,704 bp deletion
on chromosome 3, which spans only one known gene,
2810410M20Rik. The zoom-in array clearly demon-
strated the loss of 56 probes that represented this stretch
of chromosome 3 in MIN-Os and the corresponding
tumor samples. Moreover, for the other two areas of dele-
tion, the losses of DNA were confirmed to span the same
areas in the MIN-Os and the tumors. In general, the same
small aberrations as well as large gains were seen in both
MIN-Os and tumors, suggesting that these genomic
changes were already present in the MIN-Os.
Chromosome aberrations in human breast cancer has
been studied with LOH analysis [39] and array CGH
[2,3,5,40-43]. These studies have identified regions of fre-
quent copy number changes in breast cancer. For exam-
ple, ErbB2 amplicon on 17q21 is amplified in 20–30% of
breast cancers [44]. Frequent copy number changes of cer-
tain chromosome regions are associated with BRCA1 and
BRCA2 tumors, and they can be classified by the genomic
copy number alterations [40]. More recently, Fridlyand et
al. has shown that breast tumors can be classified into
three subtypes based on the copy number alteration phe-
notypes [45]. The "mixed amplifier" group had low level
gains and losses with some recurring copy number
changes, while the others two types had either few copy
number changes ("1q/16q" group) or significant changes
encompassing nearly 60% of the genome with copy
number alterations ("complex" group). The patterns of
genome alteration in our MIN-O lines resemble those of
the first two groups. Interestingly, the majority of human
tumors in these two groups were ER positive and that
these two groups had better outcome compared to the
complex group [45]. Our MIN-O lines may better repre-
sent human breast cancers that are low grade and less
aggressive than those that are ER negative, high grade
lesions with poor outcome.
Major expression changes associated with tumorigenesis
Although there were no common genomic alterations
found among all MIN-O samples examined, there seem to
be common gene expression changes associated with the
transition from normal mammary gland to MIN-O. For
example, MIN-Os over-expressed cyclin D1 and Cdkn1a
(P21). Cyclin D1 is a well-known oncogene, which is
commonly over-expressed in human breast cancer [46].
Moreover, recent reports demonstrated that cyclin D1-
associated kinase activity, through its association with
CDK4, is required for ErbB2-dependent mammary tumor-
igenesis [47-49]. Cdkn1a (P21) was also significantly
over-expressed in the MIN-Os. Cdkn1a is a cyclin-depend-
ent kinase inhibitor and is commonly known to induce
G1 arrest via the p53 pathway [50]. However this is not
incongruous with Cdkn1a over-expression in the MIN-Os,
as p21 is often over-expressed in human cancer, and more
studies have shown p21 as a modulator of cell prolifera-
tion, rather than inhibitor [51,52]. Dysregulation of these
genes in the MIN-Os demonstrates that although these tis-
sues are phenotypically premalignant, the MIN-Os
already have molecular changes known to be associated
with tumorigenesis.
Since major molecular changes had occurred in the MIN-
Os, tumors developed from the MIN-Os had surprisingly
small genetic differences from the corresponding MIN-O
tissues. Many genes coding for extracellular proteins were
down-regulated in tumors. Among these genes, Lum and
Gsn are two genes whose association with breast cancer
has been well studied. Decreased expression of Lum is
associated with poor outcome of invasive breast cancer
[53] and down-regulation of Gsn is associated with breast
cancer progression [54].
Changes associated with aneuploidy
Each MIN-O line, established from a distinct MIN lesion
in the original transgenic mammary fat pad, has distinct
genomic and expression profiles and biological character-
istics. This is also similar to human DCIS lesions, because
DCIS is subclassified into different histological grades and
the pattern of chromosome alterations and gene expres-
sion signatures differs between different histological
grades [3,4]. MIN-Os can be classified into subgroups by
genomic and molecular profiles that reflect biological
behavior (metastatic potential, tumor latency, estrogen
sensitivity).
Genetically unstable MIN-O lines, which have multiple
whole chromosome gains, almost always had gain of
chromosome 2. AurkA was one of the genes on chromo-
some 2 that was highly over-expressed in these MIN-Os.
AurkA is localized to the spindles and its overexpression
induces aberrant mitosis that results in centrosome dupli-
cation and aneuploidy [55]. Overexpression of AurkA is
associated with cancer, including human DCIS [56,57].
Other genes involved in mitotic spindle assembly and
centrosome duplication were also over-expressed in these
MIN-Os. Ran, Kif22/Kid, Plk1 and Nde1 [58] are impor-
tant for mitotic spindle assembly [58-61]. Mitotic spindle
components, tublins alpha1 and beta6 were both over-Page 15 of 19
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separation, and controls the onset of G2/M transition in
the cell cycle by activating cdc25c [62]. Interestingly, beta-
tubulin and cdc25c are substrates of Plk1 [61]. Other sub-
strates of Plk1 are subunits of anaphase promoting com-
plex (APC), which regulates progression and exit through
mitosis by proteolysis of cell cycle regulators [59]. Two
APC related genes, a component of APC, Apc11, and an
activator of APC, cdc20, were both up-regulated in these
MIN-Os. APC/cdc20 complex is important for metaphase
to anaphase transition [59]. These genes highlight dysreg-
ulation of G2/M phase, especially during metaphase/ana-
phase when sister chromatids and spindle poles separate.
Changes associated with metastasis
Highly metastatic MIN-O lines had alteration of genes
involved in immune response and apoptotic processes.
Recently, studies have shown that the inflammation proc-
ess is closely linked to cancer development [63,64]. Innate
immune systems promote tumorigenesis by producing
factors that activate tumor associated cells and changes
stromal microenvironment [65]. It is believed that
changes in apoptotic tumor cell death pattern affect the
tumor microenvironment and the associated immune
response [66]. In particular, for the metastatic processes,
tumor cells utilize many of the same factors, such as adhe-
sion molecules, chemokines and receptors, used by
inflammatory cells [67]. In the Tg(PyVmT) model, lack of
functional macrophages inhibits the development of
invasive mammary carcinoma and pulmonary metastasis
[68], and other factors that regulate tumor microenviron-
ment also affect the metastatic potential [69-72]. Gas6 is
the ligand for Axl receptor tyrosine kinase, which regulates
immune system and inhibits apoptosis [73,74]. Bcl6 is a
transcriptional regulator that has an anti-apoptotic role
and also affects humoral immune response [75]. Both of
these genes were highly over-expressed in both metastatic
MIN-O lines. Moreover, the expression of ICAM-1, an
endothelial intercellular adhesion molecule was down-
regulated in these MIN-Os. ICAM-1 is known to be down-
regulated by tumor derived angiogenic factors in order to
inhibit leukocyte infiltration and to escape from anti-
tumor immune surveillance [76,77]. These expression
changes suggest the alteration of the genes related to the
immune modulation in these MIN-Os, which may con-
tribute to the development of tumor associated environ-
ment that promote migration and invasion.
The "Metastatic signature gene set" [35] was not differen-
tially expressed between the metastatic and non-meta-
static MIN-O lines. This seems to be contradictory to the
results by Qiu et al [36] in which the signature gene set
was predictive of metastatic behaviour of Tg(PyVmT)
tumors. However, this study compares MIN-Os with dif-
ferent metastatic potentials, which express PyVmT as the
initiating oncogene in the same genetic background
(FVB), and is fundamentally different from the study by
Qiu et al in which Tg(PyVmT) tumors from various
genetic backgrounds were compared. Thus, while the met-
astatic signature gene set may be effective in classifying
metastatic disease from a group of genetically polymor-
phic samples, the MIN-O mouse lines will be useful for
investigating specific molecular mechanisms responsible
for metastasis in the disease tissues.
Changes associated with estrogen dependence
ER status of the MIN-Os, in general, reflected the ovarian
hormone sensitivity of the lesions. The 8w-B and 8w-D
lines, which were associated with nuclear ER-positive
MIN-O cells, were the most sensitive to the ovariectomy.
In all four MIN-O lines studied, significantly less ER-pos-
itive cells were found in the tumors from the intact hosts,
and in the MIN-Os from the ovariectomized hosts.
Two common functions that were affected in the estrogen
sensitive MIN-O lines were steroid biosynthesis and ang-
iogenesis. Significance of these two functions as well as
the expression differences in the ERs and aromatase may
represent the difference in estrogen mediated signaling in
the 8w-B and D MIN-Os from the rest of the MIN-O lines,
since estrogen modulates endothelial cell behavior,
including angiogensis [78]. This concept is further sup-
ported by the dysregulation of genes that are known to be
regulated by estrogen or ER, such as Cyp1b1 [79], Nf-kB2
[80], RelB, Strn [81], Fbln1 [82] or genes that interact with
estrogen or ER, such as Abcg1, Gnai2, and Jun [83]. The
down-regulation of two Nf-kB family members, Nf-kB2
and RelB, maybe significant since ER alpha is known to
inhibit the Nf-kB activity by various mechanisms, includ-
ing direct binding to the Nf-kB complex to inhibit tran-
scriptional activation [80]. Jun was up-regulated in
estrogen sensitive MIN-Os. ER activates transcription at
AP-1 sites via interaction with Jun/Fos/coactivator com-
plex [83]. Dysregulation of these genes seems to draw a
picture of increase ER and estrogen activities in these MIN-
Os.
Conclusion
In summary, in this mouse model of breast cancer, the
majority of the molecular changes responsible for tumor-
igenesis are already present in early premalignant lesions.
The progression to invasive carcinoma is associated with
only few additional changes, and these changes are not
common in all tumors. Moreover, the molecular hetero-
geneity of the premalignant lesions represents phenotypic
differences of these lesions. Thus, the MIN-O mouse
model recapitulates both the preencoding and heteroge-
neity found in early human breast lesions and may be
used as a high fidelity model for the biology of human
breast cancer.Page 16 of 19
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